FogPharma announced a $145 million Series E financing round led by Nextech Invest to support ongoing clinical development of FOG-001 and accelerate Helicon peptide portfolio.

Mar 01, 2024•almost 2 years ago

Amount Raised

$145 Million

Round Type

series e

CambridgeBiotechnologyHealth CareTherapeuticsPharmaceutical

Investors

Milky Way InvestmentsInvusVen Bio PartnersFarallon Capital ManagementT. Rowe Price Associates, Inc.Cormorant Asset ManagementGvFidelity Management & Research CompanyArch Venture PartnersSixty Degree CapitalCatalio Capital ManagementSymbiosisForesite CapitalSamsara BiocapitalMarshall WaceGeneral CatalystRock Springs CapitalRa Capital ManagementNextech Invest

Description

FogPharma successfully closed a $145 million Series E financing round led by Nextech Invest, with participation from other new investors including RA Capital Management, Rock Springs Capital, General Catalyst, Marshall Wace, Samsara Biocapital, Foresite Capital, Symbiosis, Catalio Capital Management, Sixty Degree Capital, and former chairman and CEO of Johnson & Johnson, Alex Gorsky. The financing will support the ongoing clinical development of FOG-001 and accelerate the development of its robust portfolio of unique discovery programs.

Company Information

Company

FogPharma

Location

30 ACORN PARK DRIVE

Cambridge, Massachusetts, United States

About

FogPharma is developing a new class of drugs to address the limitations of today’s precision medicines and achieve universal druggability. The company is pioneering the discovery, development and commercialization of HeliconTM peptides, a new drug modality that uniquely combines the broad targeting power of monoclonal antibodies with the cell-penetrating ability of small molecules. HeliconTM peptides hold the promise, not only to drug nearly all human disease drivers, but also to do so with unrivaled speed and scalability.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends